Change search
ReferencesLink to record
Permanent link

Direct link
Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Pediatrics.
McGill Univ, Fac Sci, Montreal, PQ, Canada..
Univ British Columbia, Fac Med, Vancouver, BC, Canada..
Univ Western Ontario, Dept Med, London, ON, Canada..
Show others and affiliations
2016 (English)In: Allergy, Asthma & Clinical Immunology, ISSN 1710-1484, E-ISSN 1710-1492, Vol. 12, 11Article in journal (Refereed) PublishedText
Abstract [en]

Background: Food allergy is the most common cause of anaphylaxis in children. Intramuscular delivery of epinephrine auto-injectors (EAI) is the standard of care for the treatment of anaphylaxis. We examined if children and adolescents at risk of anaphylaxis weighing 15-30 kg and >30 kg would receive epinephrine into the intramuscular space with the currently available EAI in North America and Europe. Methods: The distance from skin to muscle (STMD) and skin to bone (STBD) on the mid third anterolateral area of the right thigh was measured by ultrasound applying either high pressure ((max)) or slight pressure ((min)) in 102 children weighing 15-30 kg (group 1) and 100 children and adolescents, weighing more than 30 kg (group 2). Results: Using a high pressure EAI (HPEAI), Epipen Jr (R) and Auvi-Q (R)/Allerject (R) 0.15 mg, 11/102 (11 %) children in group 1 and 38/102 (38 %) using another HPEAI, Jext (R), had a STMDmax that showed a risk of intraosseous injection. There was a 1 % risk of subcutaneous injection with these devices. There was no risk of intraosseous injection using a low pressure EAI (LPEAI), Emerade (R). In group 2, the risk of intraosseous injection using a HPEAI was 3 % and no risk using a LPEAI. However, the risk of subcutaneous injection using HPEAI was 9 % and using LPEAI was 2 %. Conclusion: There is a risk of intraosseous injection using HPEAI (Epipen (R)/Epipen Jr (R), Auvi-Q (R)/Allerject (R) and especially Jext (R)) in children at risk of anaphylaxis. There was also a risk of subcutaneous injection using the currently available HPEAI in children and adolescents.

Place, publisher, year, edition, pages
2016. Vol. 12, 11
Keyword [en]
Anaphylaxis, Food allergy, Epinephrine, Epinephrine auto-injector, Allergy, Skin to bone distance, Skin to muscle distance, Intramuscular, Subcutaneous, Epimysium
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-282806DOI: 10.1186/s13223-016-0110-8ISI: 000371761600001PubMedID: 26949403OAI: diva2:919121
Available from: 2016-04-13 Created: 2016-04-07 Last updated: 2016-04-13Bibliographically approved

Open Access in DiVA

fulltext(929 kB)13 downloads
File information
File name FULLTEXT01.pdfFile size 929 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Dreborg, Sten
By organisation
In the same journal
Allergy, Asthma & Clinical Immunology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 13 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 37 hits
ReferencesLink to record
Permanent link

Direct link